Scinai Immunotherapeutics Statistics
Want to see SCNI full AI Analyst Report?
Scinai Immunotherapeutics (SCNI) Stock Statistics & Valuation Metrics
Total Valuation
Scinai Immunotherapeutics has a market cap or net worth of $504.08K. The enterprise value is $8.12M.
- Market Cap
- $504.08K
- Enterprise Value
- $8.12M
Share Statistics
Scinai Immunotherapeutics has 1,353,228 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,353,228
- Owned by Insiders
- ―
- Owned by Institutions
- 0.37%
Financial Efficiency
Scinai Immunotherapeutics’s return on equity (ROE) is -1.03 and return on invested capital (ROIC) is -72.73%.
- Return on Equity (ROE)
- -1.03
- Return on Assets (ROA)
- -0.71
- Return on Invested Capital (ROIC)
- -72.73%
- Return on Capital Employed (ROCE)
- -0.75
- Revenue Per Employee
- 29.13K
- Profits Per Employee
- -184.60K
- Employee Count
- 45
- Asset Turnover
- 0.11
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Scinai Immunotherapeutics is 0.00. Scinai Immunotherapeutics’s PEG ratio is 0.00.
- PE Ratio
- 0.00
- PS Ratio
- 0.07
- PB Ratio
- 0.01
- Price to FCF
- -0.03
- Price to Operating Cash Flow
- -0.01
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Scinai Immunotherapeutics had revenue of 1.31M and earned -8.31M in profits. Earnings per share was -36.00.
- Revenue
- 1.31M
- Gross Profit
- -2.65M
- Operating Income
- -7.54M
- Pretax Income
- -8.31M
- Net Income
- -8.31M
- EBITDA
- -6.53M
- Earnings Per Share (EPS)
- -36.00
Cash Flow
In the last 12 months, operating cash flow was -7.55M and capital expenditures -236,807, giving a free cash flow of -7.79M billion.
- Operating Cash Flow
- -7.55M
- Free Cash Flow
- -7.79M
- Free Cash Flow per Share
- -32.38
Dividends & Yields
Scinai Immunotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -4044.99%
- Earnings Yield
- -2816.62%
Stock Price Statistics
- Beta
- 1.36
- 52-Week Price Change
- -96.13%
- 50-Day Moving Average
- 1.09
- 200-Day Moving Average
- 3.86
- Relative Strength Index (RSI)
- 23.81
- Average Volume (3m)
- 2.16M
Important Dates
Scinai Immunotherapeutics upcoming earnings date is May 13, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- May 13, 2027
- Ex-Dividend Date
- ―
Financial Position
Scinai Immunotherapeutics as a current ratio of 1.30, with Debt / Equity ratio of 27.98%
- Current Ratio
- 1.30
- Quick Ratio
- 1.30
- Debt to Market Cap
- 0.18
- Net Debt to EBITDA
- -0.09
- Interest Coverage Ratio
- -21.01
Taxes
In the past 12 months, Scinai Immunotherapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Scinai Immunotherapeutics EV to EBITDA ratio is -0.29, with an EV/FCF ratio of -0.24.
- EV to Sales
- 0.61
- EV to EBITDA
- -0.29
- EV to Free Cash Flow
- -0.24
- EV to Operating Cash Flow
- -0.25
Balance Sheet
Scinai Immunotherapeutics has $1.71M in cash and marketable securities with $3.39M in debt, giving a net cash position of -$1.68M billion.
- Cash & Marketable Securities
- $1.71M
- Total Debt
- $3.39M
- Net Cash
- -$1.68M
- Net Cash Per Share
- -$1.24
- Tangible Book Value Per Share
- $44.54
Margins
Gross margin is -119.47%, with operating margin of -275.36%, and net profit margin of -81.92%.
- Gross Margin
- -119.47%
- Operating Margin
- -275.36%
- Pretax Margin
- -81.92%
- Net Profit Margin
- -81.92%
- EBITDA Margin
- -212.80%
- EBIT Margin
- -275.36%
Analyst Forecast
The average price target for Scinai Immunotherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 143.06%
- EPS Growth Forecast
- 94.98%
Scores
- Smart Score
- ―
- AI Score
- 42

